Jiangsu Yahong Meditech Co. Ltd.

Asieris Pharmaceuticals announced on the evening of October 7 that it has signed a conditional exclusive licensing agreement with Theramex HQ UK Limited. Theramex will obtain exclusive rights to APL-1702, marketed as CEVIRA, in European countries as well as Australia, New Zealand and Turkey, while the company retains related rights in the rest of the world. Under the agreement, the company will receive an upfront payment of 15 million US dollars, a near-term regulatory milestone payment of 11 million US dollars, as well as commercial milestone payments and tiered sales royalties, bringing the total transaction value to more than 250 million US dollars. The announcement showed that CEVIRA is a first-in-class photodynamic therapy product, consisting of hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic therapy light device, achieving a breakthrough in treatment through innovative local administration and an intravaginal cold light source design. The product offers unique advantages in treatment, including precise targeted clearance of lesions, immune clearance of HPV, and protection of fertility.

Feilong Shares announced that net profit attributable to shareholders for the first three quarters of 2026 is expected to be between 95 million yuan and 117 million yuan, down 59.20% to 66.87% year on year, mainly due to the combined impact of multiple phased factors including intensifying industry competition, rising raw material prices, exchange rate fluctuations, and new businesses still in the incubation period. At this stage, revenue from non-automotive businesses accounts for a relatively low proportion of overall revenue. New Asia Technology is planning to acquire a controlling stake in Shanghai Qiyuan Gas Development Co., Ltd. through the issuance of shares and cash payment, and to raise supporting funds. The transaction is expected to constitute a major asset restructuring, and trading in the company's securities has been suspended since the market opened on October 8, 2026. Huahai Pharmaceutical expects net profit for the first three quarters of 2026 to be between 1.028 billion yuan and 1.103 billion yuan, up 170% to 190% year on year, mainly due to a significant increase in sales revenue from the active pharmaceutical ingredients business, expansion of products winning bids under centralized procurement in the domestic finished drug business, a turnaround to profitability in the US finished drug business, as well as gains from winning an arbitration and a reduction in research and development expenses. Asieris Pharmaceuticals has signed a conditional exclusive license agreement with Theramex, under which Theramex obtains exclusive rights to APL-1702 in European countries as well as Australia, New Zealand, and Turkey. The company will receive an upfront payment of 15 million US dollars, a near-term regulatory milestone payment of 11 million US dollars, as well as commercial milestone payments and tiered sales royalties, with the total transaction value exceeding 250 million US dollars. COSCO Shipping Holdings has completed its A-share repurchase, actually repurchasing 50.0175 million shares, accounting for 0.3276% of total share capital, with a repurchase amount of 755 million yuan and a repurchase price range of 13.69 yuan to 16.42 yuan per share. The company will cancel the repurchased shares on October 8.

Baylink Biosciences Inc, a controlled subsidiary of Yahong Medtech, has received approval from the U.S. Food and Drug Administration for an investigational new drug application for APL-2501 for the treatment of advanced solid tumors. APL-2501 is an antibody-drug conjugate based on a topoisomerase inhibitor, expected to be useful in treating multiple advanced solid tumors such as ovarian cancer and non-small cell lung cancer. In the first quarter of 2026, Yahong Medtech recorded revenue of 71.09 million yuan and a net loss attributable to the parent company of 112 million yuan.